Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 20,400 shares, an increase of 39.7% from the November 15th total of 14,600 shares. Based on an average daily volume of 252,600 shares, the short-interest ratio is presently 0.1 days.

Chugai Pharmaceutical Price Performance

Shares of OTCMKTS:CHGCY traded down $0.60 during trading hours on Friday, hitting $21.47. 84,614 shares of the company’s stock traded hands, compared to its average volume of 127,388. The firm has a market capitalization of $70.64 billion, a P/E ratio of 27.53 and a beta of 0.82. The business has a fifty day moving average price of $22.82 and a 200-day moving average price of $21.36. Chugai Pharmaceutical has a 1 year low of $14.52 and a 1 year high of $26.00.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.